 | • レポートコード：MRC2304A003 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、229ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に4,662.99百万ドルであった世界の髄膜炎菌ワクチン市場規模が2022年に5,027.78百万ドルに到達し、2027年までにCAGR 9.24％で成長して7,927.11百万ドルへと拡大すると予測しています。当調査資料では、髄膜炎菌ワクチンの世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（混合ワクチン、コンジュゲートワクチン、血清群B髄膜炎菌（MenB）ワクチン、多糖体ワクチン）分析、カテゴリー別（筋肉内注射、皮下注射）分析、投与タイプ別（追加接種、一次予防接種）分析、エンドユーザー別（病院薬局、小児科クリニック、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、Astellas Pharma Inc.、AstraZeneca PLC、Bio-Manguinhos、Bio-Med (P) Limited、CanSino Biologics Inc.、Chongqing Zhifei Biological Products Co., Ltd.、GlaxoSmithKline PLC、Incepta Pharmaceuticals Ltd.、Merck & Co., Inc.、Mitsubishi Tanabe Pharma Corporation、Nanolekなどが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の髄膜炎菌ワクチン市場規模：種類別 - 混合ワクチンの市場規模 - コンジュゲートワクチンの市場規模 - 血清群B髄膜炎菌（MenB）ワクチンの市場規模 - 多糖体ワクチンの市場規模 ・世界の髄膜炎菌ワクチン市場規模：カテゴリー別 - 筋肉内注射の市場規模 - 皮下注射の市場規模 ・世界の髄膜炎菌ワクチン市場規模：投与タイプ別 - 追加接種の市場規模 - 一次予防接種の市場規模 ・世界の髄膜炎菌ワクチン市場規模：エンドユーザー別 - 病院薬局における市場規模 - 小児科クリニックにおける市場規模 - 小売薬局における市場規模 ・世界の髄膜炎菌ワクチン市場規模：地域別 - 南北アメリカの髄膜炎菌ワクチン市場規模 アメリカの髄膜炎菌ワクチン市場規模 カナダの髄膜炎菌ワクチン市場規模 ブラジルの髄膜炎菌ワクチン市場規模 ... - アジア太平洋の髄膜炎菌ワクチン市場規模 日本の髄膜炎菌ワクチン市場規模 中国の髄膜炎菌ワクチン市場規模 インドの髄膜炎菌ワクチン市場規模 韓国の髄膜炎菌ワクチン市場規模 台湾の髄膜炎菌ワクチン市場規模 ... - ヨーロッパ/中東/アフリカの髄膜炎菌ワクチン市場規模 イギリスの髄膜炎菌ワクチン市場規模 ドイツの髄膜炎菌ワクチン市場規模 フランスの髄膜炎菌ワクチン市場規模 ロシアの髄膜炎菌ワクチン市場規模 ... - その他地域の髄膜炎菌ワクチン市場規模 ・競争状況 ・企業情報 |
The Global Meningococcal Vaccines Market size was estimated at USD 4,662.99 million in 2021 and expected to reach USD 5,027.78 million in 2022, and is projected to grow at a CAGR 9.24% to reach USD 7,927.11 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Meningococcal Vaccines to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Combination Vaccines, Conjugate Vaccines, Men B Vaccines, and Polysaccharide Vaccines. The Combination Vaccines is further studied across MenHibrix and Menitorix. The Conjugate Vaccines is further studied across Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, and NmVac4-DT. The Men B Vaccines is further studied across Bexsero and Trumenba. The Polysaccharide Vaccines is further studied across Mencevax, Menomune, and NmVac4.
Based on Category, the market was studied across Intramuscular and Subcutaneous.
Based on Dosage Type, the market was studied across Booster Vaccination and Primary Vaccination.
Based on End User, the market was studied across Hospital Pharmacies, Pediatric Clinic, and Retail Pharmacies.
Based on Target Group, the market was studied across Adult, Preteen, and Teenager.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Meningococcal Vaccines market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Meningococcal Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Meningococcal Vaccines Market, including Astellas Pharma Inc., AstraZeneca PLC, Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Walvax Biotechnology Co., Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Meningococcal Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Meningococcal Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Meningococcal Vaccines Market?
4. What is the competitive strategic window for opportunities in the Global Meningococcal Vaccines Market?
5. What are the technology trends and regulatory frameworks in the Global Meningococcal Vaccines Market?
6. What is the market share of the leading vendors in the Global Meningococcal Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the Global Meningococcal Vaccines Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Incidence of Meningitis Across the World
5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
5.1.2. Restraints
5.1.2.1. High Cost of Meningococcal Vaccines Production
5.1.3. Opportunities
5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
5.1.4. Challenges
5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
5.2. Cumulative Impact of COVID-19
6. Meningococcal Vaccines Market, by Type
6.1. Introduction
6.2. Combination Vaccines
6.3.1. MenHibrix
6.3.2. Menitorix
6.3. Conjugate Vaccines
6.4.1. Menactra
6.4.2. MenAfriVac
6.4.3. Meningitec
6.4.4. Menjugate
6.4.5. Menveo
6.4.6. NeisVac-C
6.4.7. Nimenrix
6.4.8. NmVac4-DT
6.4. Men B Vaccines
6.5.1. Bexsero
6.5.2. Trumenba
6.5. Polysaccharide Vaccines
6.6.1. Mencevax
6.6.2. Menomune
6.6.3. NmVac4
7. Meningococcal Vaccines Market, by Category
7.1. Introduction
7.2. Intramuscular
7.3. Subcutaneous
8. Meningococcal Vaccines Market, by Dosage Type
8.1. Introduction
8.2. Booster Vaccination
8.3. Primary Vaccination
9. Meningococcal Vaccines Market, by End User
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Pediatric Clinic
9.4. Retail Pharmacies
10. Meningococcal Vaccines Market, by Target Group
10.1. Introduction
10.2. Adult
10.3. Preteen
10.4. Teenager
11. Americas Meningococcal Vaccines Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Meningococcal Vaccines Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Meningococcal Vaccines Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Astellas Pharma Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. AstraZeneca PLC
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Bio-Manguinhos
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Bio-Med (P) Limited
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. CanSino Biologics Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Chongqing Zhifei Biological Products Co., Ltd.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. GlaxoSmithKline PLC
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Incepta Pharmaceuticals Ltd.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Merck & Co., Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Mitsubishi Tanabe Pharma Corporation
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Nanolek, LLC
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Novartis AG
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Petrovax Pharm
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Pfizer Inc.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Sanofi S.A.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Serum Institute of India Pvt. Ltd.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Taj Pharmaceuticals Limited
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Walvax Biotechnology Co., Ltd.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing